9 年
手机商铺
技术资料/正文
1237 人阅读发布时间:2025-01-07 15:55
传统抗体制备方法主要是依赖于动物免疫及杂交瘤细胞融合,此法存在抗体表达量偏低、且重复性较差的缺点。而利用重组抗体表达技术,无需经历免疫阶段,即可快速实现单克隆抗体的大量重复生产,降低批间差异性。
科研工作者提供抗体序列,即可通过基于哺乳动物细胞表达系统,利用自主研发的高表达载体,转染NS0/CHO/HEK293细胞,进行重组抗体生产。项目完成后最终交付≥1 mg,> 90%纯度的重组抗体。同时,也可以根据客户的批量生产要求,提供克级的高质量重组抗体。
孚博生物优势供应重组抗体产品,欢迎您的垂询!
服务流程:
1. 生物信息学方法分析抗体序列并预测抗体结构
2. 基因合成&亚克隆,1~2周
— 抗体结构分析及 密码子优化
— 基因合成&高表达载体构建
3. 质粒抽提,1-2周
— 转染级别质粒抽提
4. 瞬时转染表达与纯化,2-3周
— 瞬时转染
— 表达小试与检测
— 亲和纯化与多步纯化
— 质量检测QC/QA
5. 稳定细胞株筛选(可选)
— 大量及重复重组抗体生产
拥有完善成熟的哺乳动物蛋白表达平台,结合抗体测序、抗体纯化、抗体亲和力成熟等先进平台能为客户提供优质的重组抗体定制服务,包含鼠源单克隆抗体测序及表达、更换恒定区亚型的嵌合抗体表达,抗体人源化改造及表达等服务。
孚博生物可提供三百多种科研级重组药物抗体类似物,提供现货和定制服务:
| adalimumab | glembatumumab vedotin | mirzotamab clezutoclax | concizumab | ustekinumab | robatumumab | panobacumab | CAT-2200 |
| alemtuzumab | gosuranemab | mitazalimab | crenezumab | vedolizumab | romilkimab | praluzatamab ravtansine | CBTAU-24.1 |
| alirocumab | GSK 679586 | narnatumab | dapirolizumab pegol | afasevikumab | rontalizumab | radretumab | CDP571 |
| atezolizumab | GSK 933776 | navicixizumab | dostarlimab | AGS-009 | rosopatamab tetraxetan | samalizumab | cevostamab |
| avelumab | ianalumab | NI-0701 | envafolimab | AGS67E | ruplizumab | tarextumab | Chugai SK2 |
| basiliximab | icrucumab | ongericimab | epratuzumab | alsevalimab | sabatolimab | TOL101 | CNTO 2125 |
| belantamab mafodotin | ieramilimab | onvatilimab | etrolizumab | ALX-0141 | sacituzumab govitecan | ulocuplumab | CNTO 4088 |
| belimumab | imalumab | opucolimab | evinacumab | AMG 811 | sasanlimab | vandortuzumab vedotin | CNTO 607 |
| benralizumab | imgatuzumab | PAT-SM6 | faricimab | amivantamab | semorinemab | varlilumab | CNTO5429 |
| bevacizumab | inclacumab | pavurutamab | farletuzumab | apamistamab | seribantumab | vunakizumab | cofetuzumab |
| blinatumomab | indusatumab vedotin | perakizumab | fasinumab | aprutumab | setrusumab | AB023 | demupitamab |
| brentuximab vedotin | iscalimab | petosemtamab | feladilimab | ASG-5ME | sevirumab | AbGn-168 | DISC0280 |
| brodalumab | istiratumab | PF-03732010 | felzartamab | atinumab | sifalimumab | abrilumab | disitamab vedotin |
| brolucizumab | itepekimab | PF-06263507 | figitumumab | azintuxizumab vedotin | simtuzumab | ABX-IL8 | DLX212 |
| burosumab | itolizumab | PF-06342674 | fulranumab | bapotulimab | sonelokimab | actoxumab | DLX212 |
| canakinumab | ivuxolimab | PG110 | galiximab | bepranemab | sonepcizumab | adecatumumab | DX-2647 |
| caplacizumab | labetuzumab govitecan | plamotamab | ganitumab | bivatuzumab mertansine | talacotuzumab | AGS-1C4D4 | elsilimomab |
| cemiplimab-rwlc | lacnotuzumab | prasinezumab | gantenerumab | brontictuzumab | talizumab | alacizumab pegol | erlizumab |
| certolizumab pegol | lacutamab | ralpancizumab | gevokizumab | budigalimab | telazorlimab | amatuximab | ESBA 105 |
| cetuximab | ladiratuzumab vedotin | RO5458640 | girentuximab | CDP484 | tesidolumab | AMG 714 | FM101 |
| daclizumab | landogrozumab | rolinsatamab talirine | lampalizumab | cendakimab | tesnatilimab | anetumab ravtansine | futuximab |
| daratumumab | lecanemab | rosmantuzumab | lebrikizumab | cergutuzumab amunaleukin | tigatuzumab | anrukinzumab | giloralimab |
| denosumab | lendalizumab | SAIT301 | lenzilumab | cibisatamab | tisotumab vedotin | apitegromab | glofitamab |
| dinutuximab | lifastuzumab vedotin | samrotamab vedotin | levilimab | citatuzumab bogatox | TNX-832 | APX005 | H2L6 |
| dupilumab | lirilumab | selicrelumab | ligelizumab | cosibelimab | tomaralimab | ascrinvacumab | Hersintuzumab |
| durvalumab | loncastuximab tesirine | serclutamab talirine | margetuximab | crotedumab | tomuzotuximab | astegolimab | hMAK195 |
| eculizumab | lorvotuzumab mertansine | sibrotuzumab | mirikizumab | CSL311 | tovetumab | avdoralimab | IMC-2C5 |
| efalizumab | lulizumab pegol | siplizumab | mirvetuximab soravtansine | cudarolimab | tregalizumab | balstilimab | Imclone 6.64 |
| elotuzumab | lumiliximab | sirtratumab vedotin | motavizumab | depatuxizumab | trevogrumab | batoclimab | Immunomedics hA19 |
| emapalumab | lutikizumab | sofituzumab vedotin | narsoplimab | dezamizumab | TRU-015 | befovacimab | Immunomedics hA19 |
| emicizumab | LY2525623 | solitomab | nemolizumab | DFRF4539A | tusamitamab ravtansine | bersanlimab | indusatumab |
| enfortumab vedotin-ejfv | marstacimab | tabituximab barzuxetan | netakimab | dilpacimab | urelumab | bezlotoxumab | isecarosmab |
| eptinezumab-jjmr | matuzumab | TAK-701 | nimotuzumab | Duke D2C7 | vanucizumab | BHQ880 | JMW-3B3 |
| erenumab | mavrilimumab | talquetamab | onartuzumab | dusigitumab | vatelizumab | bintrafusp alfa | lilotomab |
| evolocumab | miptenalimab | tamrintamab pamozirine | otelixizumab | duvortuxizumab | veltuzumab | bleselumab | lintuzumab satetraxetan (actinium (225Ac) ) |
| fremanezumab-vfrm | MM-111 | tavolimab | otilimab | elezanumab | vibostolimab | blosozumab | LK-1 |
| galcanezumab-gnlm | murlentamab | teclistamab | patritumab | enavatuzumab | vilobelimab | cabiralizumab | M1295 |
| golimumab | namilumab | telisotuzumab | ravulizumab | encelimab | vobarilizumab | camidanlumab tesirine | manelimab |
| guselkumab | naratuximab emtansine | tepoditamab | retifanlimab | enoblituzumab | vofatamab | cantuzumab mertansine | mavezelimab |
| ibalizumab-uiyk | naxitamab | tibulizumab | rilotumumab | enoticumab | volagidemab | carlumab | MB 311 |
| ibritumomab tiuxetan | nesvacumab | tidutamab | ripertamab | etigilimab | volociximab | cinpanemab | MB 311 |
| inebilizumab-cdon | NG-101 | tilavonemab | rovalpituzumab tesirine | fianlimab | vonlerizumab | cixutumumab | MEDI2045 |
| infliximab | NI-0801 | tilvestamab | rozanolixizumab | flanvotumab | vopratelimab | cobolimab | modotuximab |
| inotuzumab ozogamicin | nipocalimab | timigutuzumab | satralizumab | FR104 | xentuzumab | codrituzumab | MOR-8457 |
| ipilimumab | NIS793 | tinurilimab | serplulimab | gatipotuzumab | zagotenemab | coltuximab ravtansine | NCI m971 |
| isatuximab-irfc | odronextamab | utomilumab | sirukumab | gatralimab | zalifrelimab | crizanlizumab | NCI m972 |
| ixekizumab | oleclumab | vantictumab | solanezumab | GSK1995057 | zanidatamab | cusatuzumab | nimacimab |
| lanadelumab | olinvacimab | vesencumab | spartalizumab | HuMax-IL8 | zelminemab | dacetuzumab | NKTT320 |
| mepolizumab | olokizumab | VGX100 | sutimlimab | icatolimab | zenocutuzumab | dalotuzumab | nurulimab |
| mogamulizumab-kpkc | omburtamab | vibecotamab | tabalumab | idactamab | ziltivekimab | dectrekumab | orilanolimab |
| moxetumomab pasudotox | ontamalimab | vorsetuzumab | tanezumab | ifabotuzumab | zuberitamab | demcizumab | ORY012 |
| natalizumab | ontuxizumab | vulinacimab | teplizumab | iladatuzumab vedotin | abagovomab | denintuzumab mafodotin | OST 577 |
| necitumumab | opicinumab | zanidatamab zovodotin | tezepelumab | IMA-026 | abituzumab | derlotuximab biotin - iodine (131I) | pasotuxizumab |
| nivolumab | oportuzumab monatox | ASK8007 | tiragolumab | imaprelimab | bimagrumab | domagrozumab | PDL241 |
| obinutuzumab | orticumab | avizakimab | tislelizumab | IMC-EB10 | gancotamab | donanemab | prolgolimab |
| ocrelizumab | osocimab | benufutamab | tralokinumab | IMGN779 | leronlimab | drozitumab | quavonlimab |
| ofatumumab | otlertuzumab | bexmarilimab | tremelimumab | IMMU-114 | naptumomab estafenatox | duligotuzumab | ragifilimab |
| olaratumab | oxelumab | BMS-986148 | ublituximab | izuralimab | roledumab | eldelumab | ravagalimab |
| omalizumab | ozanezumab | BMS-986178 | vadastuximab talirine | KHK2866 | visilizumab | emactuzumab | remtolumab |
| palivizumab | pamrevlumab | cetrelimab | zalutumumab | laprituximab emtansine | adebrelimab | EMD 273063 | revdofilimab |
| panitumumab | parsatuzumab | conatumumab | zanolimumab | lexatumumab | aducanumab | emibetuzumab | RG6125 |
| pembrolizumab | pateclizumab | crovalimab | zolbetuximab | lodapolimab | AMG 386 | enibarcimab | sapelizumab |
| pertuzumab | pepinemab | efungumab | 7A7 | lodelcizumab | andecaliximab | enokizumab | SAR252067 |
| polatuzumab vedotin-piiq | pidilizumab | enapotamab vedotin | AB-25E9 | losatuxizumab vedotin | anifrolumab | ensituximab | setoxaximab |
| ramucirumab | pimurutamab | epcoritamab | abelacimab | lumretuzumab | bapineuzumab | etaracizumab | spesolimab |
| ranibizumab | pinatuzumab vedotin | glenzocimab | abrezekimab | lupartumab amadotin | bavituximab | etokimab | sugemalimab |
| risankizumab | placulumab | indatuximab ravtansine | ABT-325 | LY2787106 | begelomab | ezabenlimab | tadocizumab |
| rituximab | plozalizumab | intetumumab | adalimumab beta | LY2928057 | bemarituzumab | fezakinumab | tafolecimab |
| romosozumab-aqqg | ponezumab | labetuzumab | APX007 | LY3022855 | bermekimab | ficlatuzumab | tebotelimab |
| sarilumab | pozelimab | letolizumab | AR20.5 | LY3022856 | bimekizumab | fletikumab | tenatumomab |
| secukinumab | prezalumab | lucatumumab | AS2886401-00 | LY3022859 | birtamimab | flotetuzumab | tilogotamab |
| siltuximab | pritoxaximab | magrolimab | AT001 | LY3076226 | bococizumab | fontolizumab | TRX1 |
| sintilimab | quetmolimab | mezagitamab | ATN-658 | MEDI 5117 | brazikumab | foralumab | upifitamab |
| tafasitamab-cxix | quilizumab | milatuzumab | axatilimab | MEDI3617 | briakinumab | foravirumab | urabrelimab |
| teprotumumab-trbw | racotumomab | monalizumab | BAY 1158061 | MEDI-547 | camrelizumab | fresolimumab | varisacumab |
| tildrakizumab-asmn | rafivirumab | mosunetuzumab | BMS-986012 | MEDI-570 | carotuximab | frovocimab | VB1-050 |
| tocilizumab | refanezumab | nidanilimab | BT-063 | MEDI-578 | clazakizumab | garadacimab | vixarelimab |
| toripalimab | relatlimab | ocaratuzumab | C705 | MINT1526A | clivatuzumab tetraxetan | garetosmab | zampilimab |
| trastuzumab | RG7652 | ozoralizumab | C836 | gimsilumab | |||
| trastuzumab emtansine | rinucumab | pacmilimab | cantuzumab ravtansine |